Edmund A. Rossi

Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC)*

David M. Goldenberg, Thomas M. Cardillo, Serengulam V. Govindan et al. · Oncotarget · 2015 · 474 citations · Full text

Pharmacy, Immunology, Oncology +17

A Novel Method of ¹⁸F Radiolabeling for PET

William J. McBride, Robert M. Sharkey, Habibe Karacay et al. · Journal of Nuclear Medicine · 2009 · 408 citations · Full text

Pharmacy, Biochemistry, Chemistry +14

Sacituzumab Govitecan (IMMU-132), an Anti-Trop-2/SN-38 Antibody–Drug Conjugate: Characterization and Efficacy in Pancreatic, Gastric, and Other Cancers

Thomas M. Cardillo, Serengulam V. Govindan, Robert M. Sharkey et al. · Bioconjugate Chemistry · 2015 · 296 citations

Medicine, Oncology, Pharmacology +17

Stably tethered multifunctional structures of defined composition made by the dock and lock method for use in cancer targeting

Edmund A. Rossi, David M. Goldenberg, Thomas M. Cardillo et al. · Proceedings of the National Academy of Sciences · 2006 · 210 citations · Full text

Pharmacy, Medicinal Chemistry, Oncology +17

Improved ¹⁸F Labeling of Peptides with a Fluoride-Aluminum-Chelate Complex

William J. McBride, Christopher D'Souza, Robert M. Sharkey et al. · Bioconjugate Chemistry · 2010 · 197 citations · Full text

Natural Sciences, Biochemistry, Chemistry +15